Myomo Inc. · AMEX:MYO
Myomo — Investor Presentation (August 2026)
17 slides from Myomo's investor presentation, August 2026
Slide 1: Investor Presentation August 2026
INVESTOR PRESENTATION AUGUST 2026 Paul R. Gudonis, Chairman and CEO David Henry, Chief Financial Officer Conquering Upper Limb Paralysis with Wearable Medical Robotics NYSE American: MYO 1
Slide 2: Legal Disclaimer
Legal Disclaimer This presentation contains forward-looking statements regarding the trading of the Company’s common stock on the NYSE American, the Company’s plans for the use of proceeds and advancing its product line, increasing its sales and marketing efforts and growing its business, the Compan
Slide 3: Investment Highlights
Investment Highlights Created New Product First-Mover Advantage Category for a Large, with Strong Competitive Unmet Need Position Medicare Reimbursement Growing Revenues from Attractive Margin Profile and New Payer Contracts Recurring Patient with Opportunity for Scale Expanding Patient Access Sourc
Slide 4: Causes of Arm and Hand Paralysis: Stroke, Nerve Injury, or Disease
Causes of Arm and Hand Paralysis: Stroke, Nerve Injury, or Disease Stroke TBI Major Dx Other Dx SCI ➢ Stroke/CVA ➢ Cerebral Palsy ➢ Traumatic Brain BPI ➢ Multiple Sclerosis Injury PI ➢ ALS ➢ Spinal Cord Injury ➢ Spinal Muscular ➢ Brachial Plexus Atrophy Injury ➢ Acute Flaccid Myelitis 4
Slide 5: Patient Journey: From Stroke to Rehab Therapy
Patient Journey: From Stroke to Rehab Therapy ONSET ACUTE SUB-ACUTE OUTPATIENT CHRONIC CARE CARE THERAPY HEMIPARESIS Incidence: (Incidence) (Prevalence) 800,000 Onset → 1 week 1 week → 6 6–12 months > 6–12 months Cases/Yr. months in US Patients are told “Get used to it – You’ll never use your arm an
Slide 6: Substantial Market Opportunity
Substantial Market Opportunity 40,000 to Senior Insured Population 400,000 to 80,000 patients 800,000 replenish the 46% patients may prevalence 54% qualify for a population MyoPro each year Surviving patients that Medicare Part B Med. Advantage also carry appropriate Source: Kaiser Family Foundation
Slide 7: Our Solution: The MyoPro Arm Brace -- Enabling Activities of Daily Living
Our Solution: The MyoPro Arm Brace -- Enabling Activities of Daily Living 7
Slide 8: How it Works: Myomo's Proprietary Technology
How it Works: Myomo’s Proprietary Technology ➢ Brain-computer interface ➢ Interpret and amplify a patient’s weak EMG signal ➢ 35 Patents in U.S. and International markets valid through 2042. 8
Slide 9: Myomo Mobility Platform: Technology and Commercial Infrastructure
Myomo Mobility Platform: Technology and Commercial Infrastructure Geographic Markets US Germany OUS Note: TBD Indications Stroke TBI SCI BPI Other Product MyoPro 3 Next - Gen MyoPro MyoPal Development Product Family Hand Pediatric Current MyoPro 2X MyoPro2X MARK Connected Training Products Motion G
Slide 10: Go to Market Approach Via Distribution Channels
Go to Market Approach Via 3 Distribution Channels Stroke TBI Orthotics & Direct-to-Patient Referrals from Advertising SCI Rehab Hospitals Prosthetics (Social Media/TV) (MyoConnect) Clinics BPI PI ------------ Recurring Patient Sources ------------ 10
Slide 11: Insurance Reimbursement Supported by Clinical Research
Insurance Reimbursement Supported by Clinical Research Subjects from our Stroke Patient Registry TBI SCI Image result for blue cross blue shield logo BPI Systematic PI review published in 2025 German Statutory Health Insurance Image result for us dept of veterans affairs logo Randomized Controlled T
Slide 12: 2026 Strategy Direction & Four Success Pillars
2026 Strategy Direction & Four Success Pillars 1. Shift to Recurring Patient Sources 3. Demonstrate operating leverage Recurring Patient Sources Revenue Growth vs. Opex Growth Q2 2026: Revenue 21% Opex 1% GM 63% → 72% 2. Increase market access with additional 4. Invest in product development and res
Slide 13: Track Record: 10 Years of Revenue Growth
Track Record: 10 Years of Revenue Growth Revenues Recurring $M Invest in Revenue Direct Billing Sources + O&P 45-47 Channel Medicare 40.9 Part B revenues 32.6 U.S and Record Int’l Int’l Expanded # and VA Growth of Payers Revenue Pivot to and VAMC’s 19.2 Direct Billing, 15.6 Higher ASP; 13.9 Commerci
Slide 14: P&L and Key Balance Sheet Metrics
P&L and Key Balance Sheet Metrics P&L Key Balance Sheet Metrics Actual Actual Actual Actual ($000's) Q2'26 Q2'25 2025 2024 Actual Actual ($000's) Q2'26 Q1'26 Revenue 11,705 9,652 40,928 32,551 COGS 3,262 3,600 14,040 9,366 Cash & Investments $ 13,452 $ 15,696 Gross Profit 8,443 6,052 26,888 23,185 W
Slide 15: Where We're Headed: Longer-Term Vision
Where We’re Headed: Longer-Term Vision ➢ > $100M in annual revenues Stroke $M Revenue 120 ➢ 70% TBI gross margin, positive EBITDA 100 and cash flow. SCI 80 ➢ Durable BPI business with recurring 60 PI patient sources. 40 20 ➢ Increased market access with 0 2025 Future improved reimbursement. ➢ Growth
Slide 16: Leadership Team & Board of Directors
Leadership Team & Board of Directors Management Team Members Board of Directors Galina Shtivelman Thomas Kirk Paul R. Gudonis VP Human Resources Lead Independent Director Chairman & CEO Leads efforts to scale human Former CEO, Hanger Clinics Scaled multiple tech co’s, largest from capital, talent ac
Slide 17: Thank You! For Additional Information
Thank You! For Additional Information: Paul R. Gudonis, CEO David Henry, CFO paul@myomo.com david.henry@myomo.com 617-401-2623 508-344-5235 17